Roberto Chiarle

Roberto Chiarle, MD

Research Associate in Pathology; Attending Hematopathologist

Associate Professor in Pathology, Harvard Medical School

  • Contact: 617-919-2662

  • Fax: 617-730-0148

Medical Services

Specialties

  • Pathology

Departments

  • Pathology
To schedule an appointment: Call 617-919-2662

Experience and Education

Education

Medical School

University of Torino Medical School, 1993

Torino, Italy

Residency, Anatomic Pathology

University of Torino Medical School, 1997

Torino, Italy

Fellowship, Hematology and Molecular Pathology

New York University Medical Center, 1997-2001

New York, NY

Research

Roberto Chiarle, MD PubMed articles

Research interests include: Mechanisms and therapy of ALK driven cancers; Mechanisms that govern the formation of chromosomal translocations in normal and neoplastic cells; Discovery of novel genetic lesions in lymphoma and solid tumors, by next-generation sequencing

Publications

Publications powered by Harvard Catalyst Profiles
  1. Voena C, Varesio LM, Zhang L, Menotti M, Poggio T, Panizza E, Wang Q, Minero VG, Fagoonee S, Compagno M, Altruda F, Monti S, Chiarle R. Oncogenic ALK regulates EMT in non-small cell lung carcinoma through repression of the epithelial splicing regulatory protein 1. Oncotarget. 2016 May 31; 7(22):33316-30.
  2. Morena D, Maestro N, Bersani F, Forni PE, Lingua MF, Foglizzo V, Šcepanovic P, Miretti S, Morotti A, Shern JF, Khan J, Ala U, Provero P, Sala V, Crepaldi T, Gasparini P, Casanova M, Ferrari A, Sozzi G, Chiarle R, Ponzetto C, Taulli R. Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes. Elife. 2016; 5.
  3. Cheong TC, Compagno M, Chiarle R. Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system. Nat Commun. 2016; 7:10934.
  4. Voena C, Chiarle R. Advances in cancer immunology and cancer immunotherapy. Discov Med. 2016 Feb; 21(114):125-33.
  5. Choudhari R, Minero VG, Menotti M, Pulito R, Brakebusch C, Compagno M, Voena C, Ambrogio C, Chiarle R. Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice. Blood. 2016 Mar 10; 127(10):1297-306.
  6. Ceccon M, Merlo ME, Mologni L, Poggio T, Varesio LM, Menotti M, Bombelli S, Rigolio R, Manazza AD, Di Giacomo F, Ambrogio C, Giudici G, Casati C, Mastini C, Compagno M, Turner SD, Gambacorti-Passerini C, Chiarle R, Voena C. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. Oncogene. 2016 Jul 21; 35(29):3854-65.
  7. Voena C, Menotti M, Mastini C, Di Giacomo F, Longo DL, Castella B, Merlo ME, Ambrogio C, Wang Q, Minero VG, Poggio T, Martinengo C, D'Amico L, Panizza E, Mologni L, Cavallo F, Altruda F, Butaney M, Capelletti M, Inghirami G, Jänne PA, Chiarle R. Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. Cancer Immunol Res. 2015 Dec; 3(12):1333-43.
  8. Voena C, Peola S, Chiarle R. The anaplastic lymphoma kinase as an oncogene in solid tumors. Front Biosci (Schol Ed). 2015; 7:269-82.
  9. Karreth FA, Reschke M, Ruocco A, Ng C, Chapuy B, Léopold V, Sjoberg M, Keane TM, Verma A, Ala U, Tay Y, Wu D, Seitzer N, Velasco-Herrera Mdel C, Bothmer A, Fung J, Langellotto F, Rodig SJ, Elemento O, Shipp MA, Adams DJ, Chiarle R, Pandolfi PP. The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo. Cell. 2015 Apr 9; 161(2):319-32.
  10. Alberti D, Protti N, Toppino A, Deagostino A, Lanzardo S, Bortolussi S, Altieri S, Voena C, Chiarle R, Geninatti Crich S, Aime S. A theranostic approach based on the use of a dual boron/Gd agent to improve the efficacy of Boron Neutron Capture Therapy in the lung cancer treatment. Nanomedicine. 2015 Apr; 11(3):741-50.
  11. Show all
  12. Blasco RB, Karaca E, Ambrogio C, Cheong TC, Karayol E, Minero VG, Voena C, Chiarle R. Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. Cell Rep. 2014 Nov 20; 9(4):1219-27.
  13. Barreca A, Martinengo C, Annaratone L, Righi L, Chiappella A, Ladetto M, Demurtas A, Chiusa L, Stacchini A, Crosetto N, van Oudenaarden A, Chiarle R. Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma. Blood Cancer J. 2014; 4:e249.
  14. Ambrogio C, Carmona FJ, Vidal A, Falcone M, Nieto P, Romero OA, Puertas S, Vizoso M, Nadal E, Poggio T, Sánchez-Céspedes M, Esteller M, Mulero F, Voena C, Chiarle R, Barbacid M, Santamaría D, Villanueva A. Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts. Cancer Res. 2014 Nov 1; 74(21):5978-88.
  15. Marino F, Orecchia V, Regis G, Musteanu M, Tassone B, Jon C, Forni M, Calautti E, Chiarle R, Eferl R, Poli V. STAT3ß controls inflammatory responses and early tumor onset in skin and colon experimental cancer models. Am J Cancer Res. 2014; 4(5):484-94.
  16. Martinengo C, Poggio T, Menotti M, Scalzo MS, Mastini C, Ambrogio C, Pellegrino E, Riera L, Piva R, Ribatti D, Pastorino F, Perri P, Ponzoni M, Wang Q, Voena C, Chiarle R. ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis. Cancer Res. 2014 Nov 1; 74(21):6094-106.
  17. Lattanzio R, La Sorda R, Facciolo F, Sioletic S, Lauriola L, Martucci R, Gallo E, Palmieri G, Evoli A, Alessandrini G, Ruco L, Rendina EA, Truini M, Chiarle R, Barreca A, Pich A, Ascani S, Remotti D, Tunesi G, Granone P, Ratto GB, Puma F, Pescarmona E, Piantelli M, Marino M, Carlini S, Cerasoli V, Corzani F, Melis E, Filippetti M, Canalini P, Palestro G, Lalle M, Ruffini E, Ceribelli A, Rinaldi M. Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study. Lung Cancer. 2014 Aug; 85(2):191-6.
  18. Gostissa M, Schwer B, Chang A, Dong J, Meyers RM, Marecki GT, Choi VW, Chiarle R, Zarrin AA, Alt FW. IgH class switching exploits a general property of two DNA breaks to be joined in cis over long chromosomal distances. Proc Natl Acad Sci U S A. 2014 Feb 18; 111(7):2644-9.
  19. Semrau S, Crosetto N, Bienko M, Boni M, Bernasconi P, Chiarle R, van Oudenaarden A. FuseFISH: robust detection of transcribed gene fusions in single cells. Cell Rep. 2014 Jan 16; 6(1):18-23.
  20. Capello M, Cappello P, Linty FC, Chiarle R, Sperduti I, Novarino A, Salacone P, Mandili G, Naccarati A, Sacerdote C, Beghelli S, Bersani S, Barbi S, Bassi C, Scarpa A, Nisticò P, Giovarelli M, Vineis P, Milella M, Novelli F. Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. J Hematol Oncol. 2013; 6:67.
  21. Piazza R, Magistroni V, Mogavero A, Andreoni F, Ambrogio C, Chiarle R, Mologni L, Bachmann PS, Lock RB, Collini P, Pelosi G, Gambacorti-Passerini C. Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex. Neoplasia. 2013 May; 15(5):511-22.
  22. Voena C, Di Giacomo F, Panizza E, D'Amico L, Boccalatte FE, Pellegrino E, Todaro M, Recupero D, Tabbò F, Ambrogio C, Martinengo C, Bonello L, Pulito R, Hamm J, Chiarle R, Cheng M, Ruggeri B, Medico E, Inghirami G. The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. Oncogenesis. 2013; 2:e43.
  23. Crosetto N, Mitra A, Silva MJ, Bienko M, Dojer N, Wang Q, Karaca E, Chiarle R, Skrzypczak M, Ginalski K, Pasero P, Rowicka M, Dikic I. Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing. Nat Methods. 2013 Apr; 10(4):361-5.
  24. Camporeale A, Marino F, Papageorgiou A, Carai P, Fornero S, Fletcher S, Page BD, Gunning P, Forni M, Chiarle R, Morello M, Jensen O, Levi R, Heymans S, Poli V. STAT3 activity is necessary and sufficient for the development of immune-mediated myocarditis in mice and promotes progression to dilated cardiomyopathy. EMBO Mol Med. 2013 Apr; 5(4):572-90.
  25. Demurtas A, Stacchini A, Aliberti S, Chiusa L, Chiarle R, Novero D. Tissue flow cytometry immunophenotyping in the diagnosis and classification of non-Hodgkin's lymphomas: a retrospective evaluation of 1,792 cases. Cytometry B Clin Cytom. 2013 Mar; 84(2):82-95.
  26. Cappello P, Rolla S, Chiarle R, Principe M, Cavallo F, Perconti G, Feo S, Giovarelli M, Novelli F. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. Gastroenterology. 2013 May; 144(5):1098-106.
  27. Chiarle R. Translocations in normal B cells and cancers: insights from new technical approaches. Adv Immunol. 2013; 117:39-71.
  28. Voena C, Chiarle R. The battle against ALK resistance: successes and setbacks. Expert Opin Investig Drugs. 2012 Dec; 21(12):1751-4.
  29. Hirsch E, Chiarle R. Calming down T cell acute leukemia. Cancer Cell. 2012 Apr 17; 21(4):449-50.
  30. Duan S, Cermak L, Pagan JK, Rossi M, Martinengo C, di Celle PF, Chapuy B, Shipp M, Chiarle R, Pagano M. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature. 2012 Jan 5; 481(7379):90-3.
  31. Chiarle R, Zhang Y, Frock RL, Lewis SM, Molinie B, Ho YJ, Myers DR, Choi VW, Compagno M, Malkin DJ, Neuberg D, Monti S, Giallourakis CC, Gostissa M, Alt FW. Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell. 2011 Sep 30; 147(1):107-19.
  32. Di Paolo D, Ambrogio C, Pastorino F, Brignole C, Martinengo C, Carosio R, Loi M, Pagnan G, Emionite L, Cilli M, Ribatti D, Allen TM, Chiarle R, Ponzoni M, Perri P. Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma. Mol Ther. 2011 Dec; 19(12):2201-12.
  33. Riera L, Lasorsa E, Bonello L, Sismondi F, Tondat F, Di Bello C, Di Celle PF, Chiarle R, Godio L, Pich A, Facchetti F, Ponzoni M, Marmont F, Zanon C, Bardelli A, Inghirami G. Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. Leuk Lymphoma. 2011 Sep; 52(9):1742-50.
  34. Martinelli P, Bonetti P, Sironi C, Pruneri G, Fumagalli C, Raviele PR, Volorio S, Pileri S, Chiarle R, McDuff FK, Tusi BK, Turner SD, Inghirami G, Pelicci PG, Colombo E. The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. Blood. 2011 Jun 16; 117(24):6617-26.
  35. Di Paolo D, Brignole C, Pastorino F, Carosio R, Zorzoli A, Rossi M, Loi M, Pagnan G, Emionite L, Cilli M, Bruno S, Chiarle R, Allen TM, Ponzoni M, Perri P. Neuroblastoma-targeted nanoparticles entrapping siRNA specifically knockdown ALK. Mol Ther. 2011 Jun; 19(6):1131-40.
  36. Gostissa M, Alt FW, Chiarle R. Mechanisms that promote and suppress chromosomal translocations in lymphocytes. Annu Rev Immunol. 2011; 29:319-50.
  37. Bachetti T, Di Paolo D, Di Lascio S, Mirisola V, Brignole C, Bellotti M, Caffa I, Ferraris C, Fiore M, Fornasari D, Chiarle R, Borghini S, Pfeffer U, Ponzoni M, Ceccherini I, Perri P. PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma. PLoS One. 2010; 5(10).
  38. Boselli D, Ragimbeau J, Orlando L, Cappello P, Capello M, Ambrogio C, Chiarle R, Marsili G, Battistini A, Giovarelli M, Pellegrini S, Novelli F. Expression of IFN?R2 mutated in a dileucine internalization motif reinstates IFN? signaling and apoptosis in human T lymphocytes. Immunol Lett. 2010 Nov 30; 134(1):17-25.
  39. Riera L, Lasorsa E, Ambrogio C, Surrenti N, Voena C, Chiarle R. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. J Biol Chem. 2010 Aug 20; 285(34):26441-50.
  40. Barbieri I, Quaglino E, Maritano D, Pannellini T, Riera L, Cavallo F, Forni G, Musiani P, Chiarle R, Poli V. Stat3 is required for anchorage-independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogene. Mol Carcinog. 2010 Feb; 49(2):114-20.
  41. Gonzalo P, Guadamillas MC, Hernández-Riquer MV, Pollán A, Grande-García A, Bartolomé RA, Vasanji A, Ambrogio C, Chiarle R, Teixidó J, Risteli J, Apte SS, del Pozo MA, Arroyo AG. MT1-MMP is required for myeloid cell fusion via regulation of Rac1 signaling. Dev Cell. 2010 Jan 19; 18(1):77-89.
  42. Zhang Y, Gostissa M, Hildebrand DG, Becker MS, Boboila C, Chiarle R, Lewis S, Alt FW. The role of mechanistic factors in promoting chromosomal translocations found in lymphoid and other cancers. Adv Immunol. 2010; 106:93-133.
  43. Fornari A, Piva R, Chiarle R, Novero D, Inghirami G. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? Hematol Oncol. 2009 Dec; 27(4):161-70.
  44. Ambrogio C, Martinengo C, Voena C, Tondat F, Riera L, di Celle PF, Inghirami G, Chiarle R. NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res. 2009 Nov 15; 69(22):8611-9.
  45. Carbone A, Vizio B, Novarino A, Mauri FA, Geuna M, Robino C, Brondino G, Prati A, Giacobino A, Campra D, Chiarle R, Fronda GR, Ciuffreda L, Bellone G. IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-18 are correlated with poor survival. J Immunother. 2009 Nov-Dec; 32(9):920-31.
  46. Cappello P, Tomaino B, Chiarle R, Ceruti P, Novarino A, Castagnoli C, Migliorini P, Perconti G, Giallongo A, Milella M, Monsurrò V, Barbi S, Scarpa A, Nisticò P, Giovarelli M, Novelli F. An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer. 2009 Aug 1; 125(3):639-48.
  47. Regis G, Icardi L, Conti L, Chiarle R, Piva R, Giovarelli M, Poli V, Novelli F. IL-6, but not IFN-gamma, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing. Leukemia. 2009 Nov; 23(11):2102-8.
  48. Barberis L, Pasquali C, Bertschy-Meier D, Cuccurullo A, Costa C, Ambrogio C, Vilbois F, Chiarle R, Wymann M, Altruda F, Rommel C, Hirsch E. Leukocyte transmigration is modulated by chemokine-mediated PI3Kgamma-dependent phosphorylation of vimentin. Eur J Immunol. 2009 Apr; 39(4):1136-46.
  49. Mastini C, Martinengo C, Inghirami G, Chiarle R. Anaplastic lymphoma kinase: an oncogene for tumor vaccination. J Mol Med (Berl). 2009 Jul; 87(7):669-77.
  50. Ambrogio C, Voena C, Manazza AD, Martinengo C, Costa C, Kirchhausen T, Hirsch E, Inghirami G, Chiarle R. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res. 2008 Nov 1; 68(21):8899-907.
  51. Barutta F, Pinach S, Giunti S, Vittone F, Forbes JM, Chiarle R, Arnstein M, Perin PC, Camussi G, Cooper ME, Gruden G. Heat shock protein expression in diabetic nephropathy. Am J Physiol Renal Physiol. 2008 Dec; 295(6):F1817-24.
  52. Boccalatte FE, Voena C, Riganti C, Bosia A, D'Amico L, Riera L, Cheng M, Ruggeri B, Jensen ON, Goss VL, Lee K, Nardone J, Rush J, Polakiewicz RD, Comb MJ, Chiarle R, Inghirami G. The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. Blood. 2009 Mar 19; 113(12):2776-90.
  53. Chiarle R, Martinengo C, Mastini C, Ambrogio C, D'Escamard V, Forni G, Inghirami G. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med. 2008 Jun; 14(6):676-80.
  54. Dewilde S, Vercelli A, Chiarle R, Poli V. Of alphas and betas: distinct and overlapping functions of STAT3 isoforms. Front Biosci. 2008; 13:6501-14.
  55. Accornero P, Lattanzio G, Mangano T, Chiarle R, Taulli R, Bersani F, Forni PE, Miretti S, Scuoppo C, Dastrù W, Christensen JG, Crepaldi T, Ponzetto C. An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors. Clin Cancer Res. 2008 Apr 1; 14(7):2220-6.
  56. Canaparo R, Serpe L, Zara GP, Chiarle R, Berta L, Frairia R. High energy shock waves (HESW) increase paclitaxel efficacy in a syngeneic model of breast cancer. Technol Cancer Res Treat. 2008 Apr; 7(2):117-24.
  57. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008 Jan; 8(1):11-23.
  58. Tomaino B, Cappello P, Capello M, Fredolini C, Ponzetto A, Novarino A, Ciuffreda L, Bertetto O, De Angelis C, Gaia E, Salacone P, Milella M, Nisticò P, Alessio M, Chiarle R, Giuffrida MG, Giovarelli M, Novelli F. Autoantibody signature in human ductal pancreatic adenocarcinoma. J Proteome Res. 2007 Oct; 6(10):4025-31.
  59. Costa C, Barberis L, Ambrogio C, Manazza AD, Patrucco E, Azzolino O, Neilsen PO, Ciraolo E, Altruda F, Prestwich GD, Chiarle R, Wymann M, Ridley A, Hirsch E. Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase gamma. Proc Natl Acad Sci U S A. 2007 Sep 4; 104(36):14354-9.
  60. Scarpino S, Di Napoli A, Stoppacciaro A, Antonelli M, Pilozzi E, Chiarle R, Palestro G, Marino M, Facciolo F, Rendina EA, Webster KE, Kinkel SA, Scott HS, Ruco L. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol. 2007 Sep; 149(3):504-12.
  61. Berto G, Camera P, Fusco C, Imarisio S, Ambrogio C, Chiarle R, Silengo L, Di Cunto F. The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinase. J Cell Sci. 2007 Jun 1; 120(Pt 11):1859-67.
  62. Voena C, Conte C, Ambrogio C, Boeri Erba E, Boccalatte F, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res. 2007 May 1; 67(9):4278-86.
  63. Crepaldi T, Bersani F, Scuoppo C, Accornero P, Prunotto C, Taulli R, Forni PE, Leo C, Chiarle R, Griffiths J, Glass DJ, Ponzetto C. Conditional activation of MET in differentiated skeletal muscle induces atrophy. J Biol Chem. 2007 Mar 2; 282(9):6812-22.
  64. Conti L, Regis G, Longo A, Bernabei P, Chiarle R, Giovarelli M, Novelli F. In the absence of IGF-1 signaling, IFN-gamma suppresses human malignant T-cell growth. Blood. 2007 Mar 15; 109(6):2496-504.
  65. Piva R, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, Boccalatte F, Costa G, Ruggeri BA, Cheng M, Chiarle R, Palestro G, Neri A, Inghirami G. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest. 2006 Dec; 116(12):3171-82.
  66. Robino C, Barilaro MR, Gino S, Chiarle R, Palestro G, Torre C. Incestuous paternity detected by STR-typing of chorionic villi isolated from archival formalin-fixed paraffin-embedded abortion material using laser microdissection. J Forensic Sci. 2006 Jan; 51(1):90-2.
  67. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell Cycle. 2005 Sep; 4(9):1131-3.
  68. Piva R, Chiarle R, Manazza AD, Taulli R, Simmons W, Ambrogio C, D'Escamard V, Pellegrino E, Ponzetto C, Palestro G, Inghirami G. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood. 2006 Jan 15; 107(2):689-97.
  69. Ambrogio C, Voena C, Manazza AD, Piva R, Riera L, Barberis L, Costa C, Tarone G, Defilippi P, Hirsch E, Boeri Erba E, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood. 2005 Dec 1; 106(12):3907-16.
  70. Manazza AD, Bonello L, Pagano M, Chiusa L, Novero D, Stacchini A, Martini G, Vitolo U, Tarella C, Inghirami G, Palestro G, Chiarle R. Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas. Am J Clin Pathol. 2005 Aug; 124(2):182-90.
  71. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, Karras JG, Levy DE, Inghirami G. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005 Jun; 11(6):623-9.
  72. Taulli R, Accornero P, Follenzi A, Mangano T, Morotti A, Scuoppo C, Forni PE, Bersani F, Crepaldi T, Chiarle R, Naldini L, Ponzetto C. RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis. Cancer Gene Ther. 2005 May; 12(5):456-63.
  73. Maritano D, Sugrue ML, Tininini S, Dewilde S, Strobl B, Fu X, Murray-Tait V, Chiarle R, Poli V. The STAT3 isoforms alpha and beta have unique and specific functions. Nat Immunol. 2004 Apr; 5(4):401-9.
  74. Papotti M, Manazza AD, Chiarle R, Bussolati G. Confocal microscope analysis and tridimensional reconstruction of papillary thyroid carcinoma nuclei. Virchows Arch. 2004 Apr; 444(4):350-5.
  75. Buttiglieri S, Deregibus MC, Bravo S, Cassoni P, Chiarle R, Bussolati B, Camussi G. Role of Pax2 in apoptosis resistance and proinvasive phenotype of Kaposi's sarcoma cells. J Biol Chem. 2004 Feb 6; 279(6):4136-43.
  76. Bonello L, Voena C, Ladetto M, Boccadoro M, Palestro G, Inghirami G, Chiarle R. BRAF gene is not mutated in plasma cell leukemia and multiple myeloma. Leukemia. 2003 Nov; 17(11):2238-40.
  77. Chiarle R, Inghirami G, Palestro G. Role of CD30 in the maturation of thymocytes and in the pathogenesis of autoimmune diseases. Pathologica. 2003 Oct; 95(5):229-30.
  78. Stacchini A, Chiarle R, Antinoro V, Demurtas A, Novero D, Palestro G. Expression of the CD31 antigen in normal B-cells and non Hodgkin's lymphomas. J Biol Regul Homeost Agents. 2003 Oct-Dec; 17(4):308-15.
  79. Sapino A, Cassoni P, Ferrero E, Bongiovanni M, Righi L, Fortunati N, Crafa P, Chiarle R, Bussolati G. Estrogen receptor alpha is a novel marker expressed by follicular dendritic cells in lymph nodes and tumor-associated lymphoid infiltrates. Am J Pathol. 2003 Oct; 163(4):1313-20.
  80. Piva R, Liu J, Chiarle R, Podda A, Pagano M, Inghirami G. In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation. Mol Cell Biol. 2002 Dec; 22(23):8375-87.
  81. Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J, Simmons WJ, Dhall G, Howes J, Piva R, Inghirami G. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood. 2003 Mar 1; 101(5):1919-27.
  82. Chiarle R, Fan Y, Piva R, Boggino H, Skolnik J, Novero D, Palestro G, De Wolf-Peeters C, Chilosi M, Pagano M, Inghirami G. S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol. 2002 Apr; 160(4):1457-66.
  83. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, Levy DE, Inghirami G. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene. 2002 Feb 7; 21(7):1038-47.
  84. Latres E, Chiarle R, Schulman BA, Pavletich NP, Pellicer A, Inghirami G, Pagano M. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci U S A. 2001 Feb 27; 98(5):2515-20.
  85. Simmons WJ, Simms M, Chiarle R, Mackay F, Tsiagbe VK, Browning J, Inghirami G, Thorbecke GJ. Induction of germinal centers by MMTV encoded superantigen on B cells. Dev Immunol. 2001; 8(3-4):201-11.
  86. Chiarle R, Pagano M, Inghirami G. The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res. 2001; 3(2):91-4.
  87. Chilosi M, Chiarle R, Lestani M, Menestrina F, Montagna L, Ambrosetti A, Prolla G, Pizzolo G, Doglioni C, Piva R, Pagano M, Inghirami G. Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia. Br J Haematol. 2000 Oct; 111(1):263-71.
  88. Miravalle L, Tokuda T, Chiarle R, Giaccone G, Bugiani O, Tagliavini F, Frangione B, Ghiso J. Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J Biol Chem. 2000 Sep 1; 275(35):27110-6.
  89. Liu J, Prolla G, Rostagno A, Chiarle R, Feiner H, Inghirami G. Initiation of translation from a downstream in-frame AUG codon on BRCA1 can generate the novel isoform protein DeltaBRCA1(17aa). Oncogene. 2000 May 25; 19(23):2767-73.
  90. Chiarle R, Budel LM, Skolnik J, Frizzera G, Chilosi M, Corato A, Pizzolo G, Magidson J, Montagnoli A, Pagano M, Maes B, De Wolf-Peeters C, Inghirami G. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood. 2000 Jan 15; 95(2):619-26.
  91. Gong JZ, Zheng S, Chiarle R, De Wolf-Peeters C, Palestro G, Frizzera G, Inghirami G. Detection of immunoglobulin kappa light chain rearrangements by polymerase chain reaction. An improved method for detecting clonal B-cell lymphoproliferative disorders. Am J Pathol. 1999 Aug; 155(2):355-63.
  92. Chiarle R, Podda A, Prolla G, Podack ER, Thorbecke GJ, Inghirami G. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol. 1999 Jul 1; 163(1):194-205.
  93. Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol. 1999 Feb; 90(2):157-64.
  94. Gaidano G, Volpe G, Pastore C, Chiarle R, Capello D, Gloghini A, Perissinotto E, Savinelli F, Bosco M, Mazza U, Pileri S, Palestro G, Carbone A, Saglio G. Detection of BCL-6 rearrangements and p53 mutations in Malt-lymphomas. Am J Hematol. 1997 Dec; 56(4):206-13.
  95. Palestro G, Ponti R, Chiusa L, Chiarle R, Geuna M, Novero D, Freilone R, Pich A. Cell proliferation, bcl-2, c-myc, p53 and apoptosis as indicators of different aggressiveness in small lymphocytic lymphoma (SLL). Eur J Haematol. 1997 Sep; 59(3):148-54.
  96. Chiarle R, Godio L, Fusi D, Soldati T, Palestro G. Pure alveolar rhabdomyosarcoma of the corpus uteri: description of a case with increased serum level of CA-125. Gynecol Oncol. 1997 Aug; 66(2):320-3.
  97. Pich A, Chiarle R, Chiusa L, Ponti R, Geuna M, Palestro G. p53 expression and proliferative activity predict survival in non-invasive thymomas. Int J Cancer. 1996 Jun 21; 69(3):180-3.
  98. Pich A, Chiarle R, Chiusa L, Ponti R, Geuna M, Casadio C, Maggi G, Palestro G. Long-term survival of thymoma patients by histologic pattern and proliferative activity. Am J Surg Pathol. 1995 Aug; 19(8):918-26.
  99. Pilotti S, Manenti G, De Gregorio L, Rilke F, Chiarle R, Pierotti MA. Identification of the same HRAS1 mutation in a primary minimally invasive follicular carcinoma of the thyroid gland and its bone metastasis developed 15 years later. Diagn Mol Pathol. 1995 Mar; 4(1):73-4.
  100. Pich A, Chiarle R, Chiusa L, Palestro G. Argyrophilic nucleolar organizer region counts predict survival in thymoma. Cancer. 1994 Sep 1; 74(5):1568-74.
To schedule an appointment: Call 617-919-2662

Locations

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close